NCT02536976

Mirabegron in Parkinson Disease and Impaired Cognition

A Clinical Trial of Mirabegron for Overactive Bladder Symptoms in Patients With Parkinson Disease and Impaired Cognition

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: HealthPartners Institute · Academic / Other
• Sex: All
• Age: 25 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

There is a high prevalence of OAB symptoms among patients with Parkinson's disease and a lack of pharmacotherapies with an acceptable side effect profile. Specifically, available anticholinergic medications have a high risk of cognitive side-effects, which preclude their use in PD patients with CI. PD can also cause a number of non-motor symptoms that are likely to be adversely affected by the currently available anticholinergic agents. Mirabegron is the first pharmacologic treatment which may not exacerbate CI, constipation, orthostatic hypotension (OH), somnolence, and dry mouth in PD.

Conditions

• Parkinson Disease
• Overactive Bladder
• Impaired Cognition

Interventions

Type	Name	Description
DRUG	mirabegron
DRUG	Placebo

Timeline

• Start date: 2015-12-01
• Primary completion: 2018-08-01
• Completion: 2018-08-01
• First posted: 2015-09-01
• Last updated: 2019-05-08
• Results posted: 2019-05-08

Locations

1 site across 1 country: United States